Iterum Therapeutics PLC (ITRM) Stock Analysis

Iterum Therapeutics PLC (ITRM) is a publicly traded company in the HEALTHCARE sector. It trades at $0.03. This page summarizes the public market data, fundamentals, and frequently asked questions for ITRM, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Iterum Therapeutics PLC currently has a Bearish sentiment score of -0.29.

About Iterum Therapeutics PLC

Iterum Therapeutics PLC is a clinical-stage pharmaceutical company dedicated to the development of innovative anti-infective therapies specifically targeting multidrug-resistant infections. Based in Dublin, Ireland, Iterum focuses on addressing significant unmet medical needs in the U.S. and European markets. By prioritizing solutions that combat antibiotic resistance, the company is establishing itself as a pivotal participant in the antimicrobial treatment sector, with a mission to enhance ...

GNG Research Analysis

GNG Research scores Iterum Therapeutics PLC (ITRM) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for ITRM.

Frequently Asked Questions

Does ITRM pay dividends?

Iterum Therapeutics PLC (ITRM) does not currently pay a regular dividend.